Increased genotype frequency of N-acetyltransferase 2 slow acetylation in patients with rheumatoid arthritis

Clinical Pharmacology and Therapeutics

Volumn 72, Issue 3, 2002, Pages 319-325

  Pawlik, Andrzej ^a,b   Ostanek, Lidia ^a   Brzosko, Iwona ^a   Gawroska Szklarz, Barbara ^a   Brzosko, Marek ^a   Da̧browska Zamojcin, Ewa ^a  

^a POMERANIAN MEDICAL UNIVERSITY   (Poland)

^b Department of Pharmacokinetics and Therapeutic Drug Monitoring ^*  (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

ACYLTRANSFERASE; ARYLAMINE ACETYLTRANSFERASE; DNA; RHEUMATOID FACTOR; UNCLASSIFIED DRUG; XENOBIOTIC AGENT;

ACETYLATION; ADULT; AGE; AGED; ALLELE; ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE COURSE; DISEASE PREDISPOSITION; DNA EXTRACTION; DNA POLYMORPHISM; ENZYME ANALYSIS; ENZYME POLYMORPHISM; FEMALE; GENE FREQUENCY; GENOTYPE; HEALTH STATUS; HUMAN; MAJOR CLINICAL STUDY; MALE; MUTATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; RISK FACTOR; STATISTICAL SIGNIFICANCE;

ACETYLATION; ADOLESCENT; ADULT; AGED; ARTHRITIS, RHEUMATOID; ARYLAMINE N-ACETYLTRANSFERASE; CHI-SQUARE DISTRIBUTION; CONFIDENCE INTERVALS; FEMALE; GENE FREQUENCY; GENOTYPE; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC;

EID: 0036739754     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1067/mcp.2002.126740     Document Type: Article

References (44)

1. The pathophysiology and treatment of rheumatoid arthritis
2. Molecular mechanism of slow acetylation of drugs and carcinogens in humans
3. N-acetyltransferase polymorphism. Comparison of phenotype and genotype in humans
4. N-acetyltransferases: Pharmacogenetics and clinical consequences of polymorphic drug metabolism
5. Arylamine N-acetyltransferase activity in man
6. Acetylation phenotypes and biological variation in a French population
7. Relationship between acetylation polymorphism and risk of atopic diseases
8. Genotype of N-acetyltransferase 2 (NAT2) polymorphism in children with immunoglobulin E-mediated food allergy
9. N-acetyltransferase (NAT2) genotype and susceptibility to sporadic Alzheimer's disease
10. Detailed genotyping demonstrates association between the slow acetylator genotype for N-acetyltransferase 2 (NAT2) and familial Parkinson's disease
11. Combined effects of well-done red meat, smoking, and rapid N-acetyltransferase 2 and CYP1A2 phenotypes in increasing colorectal cancer risk
12. N-acetyltransferase 2 polymorphisms, cigarette smoking an alcohol consumption, and oral squamous cell cancer risk
13. The enhanced bladder cancer susceptibility of NAT2 slow acetylators towards aromatic amines: A review considering ethnic differences
14. Aromatic DNA adducts and polymorphisms of CYP1A1, NAT2, and GSTM1 in breast cancer
15. Genetic polymorphisms in N-acetyltransferase-2 and microsomal epoxide hydrolase, cumulative cigarette smoking and lung cancer
16. Predominance of slow acetylators among patients with rheumatoid arthritis
17. Effect of acetylator phenotype on efficacy and toxicity of sulphasalazine in rheumatoid arthritis
18. Sulphasalazine for rheumatoid arthritis: Relationship between dose, acetylator phenotype and response to treatment
19. Acetylator phenotype and the effect of dapsone in rheumatoid arthritis
20. Acetylator phenotypes in rheumatoid arthritis patients with or without adverse drug reactions to sodium-aurothiomalate or d-penicillamine
21. Acetylator phenotype in rheumatoid arthritis
22. Acetylator polymorphism in rheumatoid arthritis
23. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis
24. A fast method for high-quality genomic DNA extraction from whole blood
25. Polymorphisms in drug-metabolizing enzymes as modifiers of cancer risk
26. Rheumatoid arthritis in US adults 1960-2
27. The incidence of rheumatoid arthritis is not related to indicators of socioeconomic deprivation
28. Rheumatoid arthritis in an urban South African Negro population
29. Rheumatoid arthritis in a rural South African Negro population
30. Low prevalence of rheumatoid arthritis in Black-Caribbeans compared with whites in inner city Manchester
31. Increased prevalence of poor sulphoxidation in patients with rheumatoid arthritis: Effect of changes in the acute phase response and second line drug treatment
32. Correlation between acetylation phenotype and genotype in Chinese women
33. Genetic polymorphism of drug metabolism in humans
34. Genetically determined N-acetylation and oxidation polymorphisms: Their clinical implications in Far Eastern Oriental populations
35. N-acetyltransferase genetics and their role in predisposition to aromatic and heterocyclic amine-induced carcinogenesis
36. The role of the human acetylation polymorphism in the metabolic activation of the food carcinogen 2-amino-3-methylimidazo[4,5-f]quinoline (IQ)
37. Cell cycle implications in the pathogenesis of rheumatoid arthritis
38. The molecular basis of rheumatoid arthritis
39. Oncogenes in rheumatoid arthritis
40. Metabolic activation and deactivation of arylamine carcinogens by recombinant human NAT1 and polymorphic NAT2 acetyltransferases
41. Acetyltransferases and susceptibility to chemicals
42. 2-Aminofluorene-DNA adduct levels in tumor-target and nontarget organs of rapid and slow acetylator Syrian hamsters congenic at the NAT2 locus